Cosmos Health Inc.

What they do

Cosmos Health operates through subsidiaries as a full-line pharmaceutical wholesaler, distributing prescription drugs, OTC products, medical devices, and nutraceuticals to retail pharmacies, hospitals, and clinics, primarily in Greece and the UK. It also manufactures and sells proprietary nutraceutical brands (Sky Premium Life, Mediterranation) and licensed branded generics, with distribution to over 1,500 pharmacies in Greece. The company is engaged in R&D for novel oncology drugs and drug repurposing and operates a telehealth platform.

Revenue drivers

• Full Line Wholesaler (CosmoFarm) — Distribution of pharmaceuticals, OTC drugs, medical devices, and other healthcare products to retail pharmacies, hospitals, and clinics; drove record distribution volumes in Q1 2026, with revenue mix shift toward wholesale impacting gross margin.
• Branded Pharmaceuticals & Generics — Production, promotion, and sale of licensed branded generics and OTC products in Europe via Greek and UK subsidiaries; capital-efficient model focused on product additions and geographic expansion.
• Nutraceuticals (Sky Premium Life, Mediterranation) — Proprietary branded nutraceuticals with over 160 product codes, manufactured by Doc Pharma; growing order activity across multiple markets; higher margin contribution than wholesale.
• Contract Manufacturing (Cana Laboratories) — Expanded contract manufacturing agreements at Cana Laboratories; contributes to revenue growth and supports global expansion efforts.

Recent performance

Q1 2026 revenue rose 30.7% year-over-year to $17.93 million, a new Q1 record, with adjusted revenue up 34.2% to $18.40 million. Gross profit fell to $1.38 million from $2.05 million in Q1 2025 due to a revenue mix shift toward wholesale and a $470,601 sales discount reversal; adjusted gross profit was $1.85 million. Net loss widened to $2.81 million from $0.82 million in Q1 2025, driven by $1.15 million in non-cash items including digital asset mark-to-market losses and foreign currency translation losses. Total liabilities decreased by $4.51 million to $42.54 million, and stockholders' equity rose 7.6% to $19.83 million as of March 31, 2026. Adjusted EBITDA was near breakeven at ($229,596).

Strategy

Management is investing in personnel, infrastructure, technology, and AI-driven efficiencies to support global growth, with U.S. expansion actively underway. The company is focused on growing its wholesale distribution footprint, expanding Sky Premium Life across multiple markets, and securing new contract manufacturing agreements at Cana Laboratories. It aims to improve the liabilities-to-assets ratio through active debt reduction, including convertible note and credit facility paydowns. The company is also pursuing product additions and geographic expansion in branded generics, while continuing R&D in oncology and drug repurposing.

Risks

• Going concern risk — The company's history of losses and uncertainty about securing additional capital raise substantial doubt about its ability to continue as a going concern within one year after the financial statement issuance date.
• Dependence on external financing — If the company cannot obtain public or private financing on acceptable terms, it may be forced to delay or eliminate R&D programs, product portfolio expansion, or commercialization efforts.
• Operating losses and cash burn — Annual net losses have persisted ($19.1M in 2025), with operating cash flow negative in every year from 2021 to 2025; cash and equivalents were only $514,702 as of March 31, 2026, before considering the $2.2M reported in the press release.
• Regulatory and competitive pressures — As a pharmaceutical and nutraceutical company, products face regulatory approval risks and competition from existing and new products in the same therapeutic categories.

Outlook

Management reports that momentum from Q1 2026 is continuing into Q2, with U.S. expansion actively underway and a 'new phase of growth' driven by strategic investments. The company expects to incur significant operating losses for the foreseeable future and may need to raise additional capital. Revenue growth is expected to be supported by new pharmacies at CosmoFarm, Sky Premium Life expansion, and contract manufacturing agreements, but adjusted profitability remains a near-term goal.